20 Jul 2023
bởiElaine Soliven
Treatment with once-weekly tirzepatide, a GIP* and GLP-1** receptor agonist, led to a substantial weight reduction among overweight or obese adults with type 2 diabetes (T2D), according to the phase III SURMOUNT-2 trial presented at ADA 2023.